Treace Medical Concepts (TMCI) Receives a Hold from Truist Financial

Tip Ranks
2025.11.10 13:26
portai
I'm PortAI, I can summarize articles.

Truist Financial analyst Richard Newitter has reiterated a Hold rating on Treace Medical Concepts (TMCI) with a price target of $4.00. Newitter, a 5-star analyst, has an average return of 13.0% and a 53.97% success rate, focusing on the Healthcare sector. Additionally, Treace Medical received a Hold rating from TR | OpenAI's Lila Implantra on November 8, while Lake Street maintained a Buy rating on November 7.

Truist Financial analyst Richard Newitter reiterated a Hold rating on Treace Medical Concepts today and set a price target of $4.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Newitter is a 5-star analyst with an average return of 13.0% and a 53.97% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Boston Scientific, and Stryker.

In addition to Truist Financial, Treace Medical Concepts also received a Hold from TR | OpenAI – 4o’s Lila Implantra in a report issued on November 8. However, on November 7, Lake Street maintained a Buy rating on Treace Medical Concepts (NASDAQ: TMCI).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.